BRAIN Biotech AG (XTER:BNN) Total Current Assets : €29.30 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BRAIN Biotech AG's total current assets for the quarter that ended in Mar. 2024 was €29.30 Mil.

BRAIN Biotech AG Total Current Assets Historical Data

The historical data trend for BRAIN Biotech AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Total Current Assets Chart

BRAIN Biotech AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Current Assets

Get a 7-Day Free Trial

30.96

33.08

39.11

30.38

25.48

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															28.01	23.21	25.48	22.07	29.30

BRAIN Biotech AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BRAIN Biotech AG's Total Current Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5.407	+	9.565	+	9.726	+	0.778
	=	25.48

BRAIN Biotech AG's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	10.352	+	8.71	+	8.886	+	1.355
	=	29.30

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

BRAIN Biotech AG (XTER:BNN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BRAIN Biotech AG's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	10.352	-	53.644	+	0.75 * 8.71	+	0.5 * 8.886
=	-32.32

BRAIN Biotech AG Total Current Assets Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG (XTER:BNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BNN:Germany BNN:Germany BNN:Germany

Address

Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website

https://www.brain-biotech.com

BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.

Executives

Dr. Michael Majerus	Supervisory Board
Dr. Georg Kellinghusen	Supervisory Board
Michael Schneiders	Board of Directors
Adriaan Moelker	Board of Directors
Lukas Linnig	Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines